Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metformin to Prevent the Metabolic Complications of Olanzapine.

Next Previous
Trial Profile

Metformin to Prevent the Metabolic Complications of Olanzapine.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metformin (Primary) ; Olanzapine
  • Indications Metabolic syndrome; Obesity
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 17 Aug 2012 Actual end date (1 Aug 2011) added as reported by ClinicalTrials.gov.
  • 01 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 16 Sep 2010 Planned end date changed from 1 Aug 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top